A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

January 12, 2017

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions
Myelodysplastic Syndromes (MDS)
Interventions
DRUG

Azacitidine

Powder for injection; taken subcutaneously (SC) or intravenous (IV); Administered on Days 1-7 of 28 days cycle or Days 1-5 of Week 1 \& Days 1-2 of Week 2 of 28 day cycle.

DRUG

Venetoclax

Oral; Tablet

Trial Locations (37)

2010

Duplicate_St. Vincent's Hospital, Darlinghurst /ID# 222846, Darlinghurst

2139

Concord Repatriation General Hospital /ID# 154958, Concord

2170

Liverpool Hospital /ID# 222410, Liverpool

2217

St George Hospital /ID# 154954, Kogarah

2298

Calvary Mater Newcastle /ID# 154957, Waratah

3004

The Alfred Hospital /ID# 154956, Melbourne

3084

Austin Health /ID# 154955, Heidelberg

4102

Duplicate_Princess Alexandra Hospital /ID# 154990, Woolloongabba

6150

Fiona Stanley Hospital /ID# 222847, Murdoch

10065

Weill Cornell Medical College /ID# 155524, New York

15260

University of Pittsburgh MC /ID# 153662, Pittsburgh

21201

University of Maryland, Baltimore /ID# 153669, Baltimore

40138

Duplicate_IRCCS AOU di Bologna - Policlinico Sant'Orsola-Malpighi /ID# 153763, Bologna

44000

Centre Hospitalier Universitaire de Nantes, Hotel Dieu -HME /ID# 153828, Nantes

50937

Universitaetsklinikum Koeln /ID# 153141, Cologne

63110

Washington University-School of Medicine /ID# 153671, St Louis

68167

Universitatsklinikum Mannheim /ID# 153140, Mannheim

75010

Hôpital Saint-Louis /ID# 153827, Paris

77030

UT MD Anderson Cancer Center /ID# 153809, Houston

81675

Klinikum rechts der Isar /ID# 153139, Munich

97239

Oregon Medical Research Center /ID# 152734, Portland

85719-1478

Duplicate_University of Arizona Cancer Center - North Campus /ID# 154155, Tucson

60637-1443

The University of Chicago Medical Center /ID# 153673, Chicago

02111-1552

Tufts Medical Center /ID# 153672, Boston

02215

Dana-Farber Cancer Institute /ID# 152735, Boston

10032-3729

Columbia University Medical Center /ID# 153661, New York

37203-1632

Tennessee Oncology-Nashville Centennial /ID# 222769, Nashville

37232-0011

Vanderbilt University Medical Center /ID# 152738, Nashville

L8V 1C3

Juravinski Cancer Centre /ID# 152947, Hamilton

01307

Duplicate_Universitaetsklinikum Carl Gus /ID# 153958, Dresden

04103

Universitaetsklinikum Leipzig /ID# 153142, Leipzig

06120

Universitaetsklinikum Halle (Saale) /ID# 153760, Halle

00161

Duplicate_Azienda Ospedaliero-Universitaria Policlinico Umberto I /ID# 153764, Rome

NR4 7UY

Norfolk and Norwich University Hospitals NHS Foundation Trust /ID# 156492, Norwich

OX3 9DU

Oxford University Hospitals NHS Foundation Trust /ID# 222567, Oxford

B15 2TH

University Hospitals Birmingham NHS Foundation Trust /ID# 158810, Birmingham

SE5 9RS

King's College Hospital NHS Foundation Trust /ID# 156489, London

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

AbbVie

INDUSTRY